A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
After five years of using the AdaptDx to identify AMD at its earliest stage and then placing patients on a treatment regimen involving modifiable risk factors, I have documented many patients having improved Rod Intercept times (improved dark adaptation) and maintaining their visual acuity.
By being able to test more patients, we’ll ultimately uncover more macular degeneration. That’s good for patients. And I think we all need to realize is that what’s good for our patients winds up being good for our practices.
I feel that the AdaptDx instrument from MacuLogix is the most significant diagnostic breakthrough in my career! We finally have an instrument that helps us diagnose AMD before vision loss occurs!
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.
Screening for macular degeneration is important because as we know, once we lose sight in our macula and once it becomes affected, there’s no getting that back. So being proactive is a lot better than being reactive.